According to CoinMeta, Google DeepMind has announced the launch of a new generation of DNA sequence model, AlphaGenome 2, which is used to predict how DNA sequences and their variations affect specific types of human cells, in order to assist in the study of the cellular origins of diseases. Building upon the AlphaGenome model released last year, this new model refines predictions from broader tissue averages to individual cell types and cell states, and also features a redesigned architectural approach. Officials claim that compared to the most advanced models prior to this, AlphaGenome 2 can identify nearly double the number of variations in gene expression within cells that can be altered. This model is now available to non-commercial research through AlphaGenome API, while commercial research is provided in a limited, non-public preview format. It is emphasized by the officials that AlphaGenome and AlphaGenome 2 are intended for research purposes only and have not yet been approved for clinical or diagnostic use.